With Oxford Nanopore Stake, Illumina Makes Another Claim In Third-Generation Sequencing
January 13, 2009
With Oxford Nanopore Stake, Illumina Makes Another Claim In Third-Generation Sequencing
Illumina made the investment to help the company develop its so-called Base technology, which couples an exonuclease and a protein nanopore for sequencing.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- At Investor Confab, Illumina Details 'Enormous' DTC Demand as Market Shifts to Less Complex Chips
May 21, 2013 / BioArray News - ICCG, Awaiting Funding, Moves Ahead with Plans to Build Database of Genomic, Phenotypic Information
May 21, 2013 / BioArray News - NorthShore Bio Develops Solid-State 'Tunable' Nanopore Chips for Sequencing-by-Degradation
May 21, 2013 / In Sequence - Startup Cambridge Epigenetix to Commercialize oxBS Technology
May 21, 2013 / In Sequence - Head-to-Head Comparison Considers RNA Sequencing Methods for Degraded, Low-Quantity RNA Samples
May 21, 2013 / In Sequence